Lila Levinson,  —

Articles by

Longer rituximab treatment intervals don’t affect safety, efficacy

People with multiple sclerosis (MS) may receive less frequent infusions of rituximab without increasing their chances of relapse or disease progression, according to a real-world study from Norway. After receiving three doses at six-month intervals, extending the time between following doses to nine months is “a safe and effective…